KalVista Pharmaceuticals (NASDAQ:KALV) Issues Quarterly Earnings Results, Misses Estimates By $0.03 EPS

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) posted its quarterly earnings results on Wednesday. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.03), Zacks reports.

KalVista Pharmaceuticals Stock Up 2.9 %

Shares of KALV traded up $0.35 during midday trading on Friday, reaching $12.60. 437,380 shares of the stock were exchanged, compared to its average volume of 430,630. The stock's 50 day simple moving average is $9.75 and its 200 day simple moving average is $10.26. The company has a market cap of $622.67 million, a P/E ratio of -3.46 and a beta of 0.76. KalVista Pharmaceuticals has a twelve month low of $7.30 and a twelve month high of $15.50.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 6,669 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $11.97, for a total value of $79,827.93. Following the transaction, the chief executive officer now directly owns 287,811 shares of the company's stock, valued at $3,445,097.67. This trade represents a 2.26 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Venrock Healthcare Capital Par purchased 43,707 shares of the business's stock in a transaction dated Thursday, January 30th. The shares were purchased at an average cost of $8.76 per share, with a total value of $382,873.32. Following the acquisition, the insider now owns 4,986,480 shares in the company, valued at $43,681,564.80. This trade represents a 0.88 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 236,055 shares of company stock worth $2,162,146 and have sold 17,292 shares worth $184,625. 10.50% of the stock is currently owned by corporate insiders.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on KALV shares. Citizens Jmp raised shares of KalVista Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 31st. JMP Securities assumed coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They issued an "outperform" rating and a $19.00 price objective for the company. Bank of America initiated coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a "buy" rating and a $22.00 target price on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Finally, TD Cowen began coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $30.00 price objective for the company. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).